Inqovi

DRUG3 trials

Sponsors

Massachusetts General Hospital, National Cancer Institute (NCI), Lachelle D. Weeks, MD, PhD

Conditions

Chronic Myelomonocytic LeukemiaClonal Cytopenia of Undetermined SignificanceCytopeniaMyelodysplastic SyndromesStem Cell Leukemia

Early Phase 1

Early Intervention in High Risk CCUS

RecruitingNCT06802146

Lachelle D. Weeks, MD, PhDClonal Cytopenia of Undetermined Significance, Cytopenia

Start: 2025-02-07End: 2028-12-01Target: 108Updated: 2026-04-23

Phase 1

Inqovi Maintenance Therapy in Myeloid Neoplasms

Active, not recruitingNCT04980404

Massachusetts General HospitalChronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Stem Cell Leukemia

Start: 2021-09-17End: 2026-11-01Target: 22Updated: 2026-03-30

Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes

TerminatedNCT05918055

National Cancer Institute (NCI)Myelodysplastic Syndromes

Start: 2023-11-14End: 2025-03-12Updated: 2025-12-02

Related Papers

A multi-site break through cancer pilot study testing the feasibility and safety of therapeutic intervention for patients with high-risk clonal cytopenia of undetermined significance (CCUS)

Blood2025-11-03

Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for <i>IDH2</i>-mutated myeloid malignancies

Blood Advances2022-09-2355 citations